Recruiting
Hepatocellular carcinoma+2
RecruitingLong-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors
InvestigationalNo placebo
Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors
InvestigationalNo placebo
- Disease:Hepatocellular carcinomaMalignant melanoma+1
- Substances:RP2RP3+1
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:RP2



